“AroCell TK 210 ELISA:
A novel proliferation biomarker to study hematological malignancies”
November 15, 2017 │10 am to 10.30 am EST
Proliferation biomarkers play a key role in monitoring malignancies, aiding making prognoses and providing early insights into the effects of therapy.
Thymidine kinase 1 (TK1) is a well-known proliferation biomarker but most current methods are based on enzyme activity methods and may under-estimate serum TK1 levels, particularly in subjects with solid tumors
The AroCell TK 210 ELISA brings the sensitivity and robustness of immunoassay to this important biomarker. Information will be presented on the value and opportunity of AroCell TK 210 ELISA as a novel translational biomarker in hematological studies.
- Role of Proliferation Biomarkers
- A review of Thymidine Kinase 1 as a Proliferation Biomarker
- Thymidine Kinase 1 in hematological malignancies
- Improved Immunoassay of TK 1 based on the TK 210 antigen – AroCell TK 210 ELISA
- Monitoring of Proliferative Disease using AroCell TK 210 ELISA
Martin Shaw has had long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA.
Staffan Eriksson is Professor in Medical and Physiological Chemistry at the Swedish University of Agricultural Sciences. Professor Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also a founder of AroCell AB and one of the inventors of the TK 210 ELISA test for measuring cell growth and turnover.